Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
Official title: A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-10-13
Completion Date
2026-12-03
Last Updated
2026-02-19
Healthy Volunteers
Yes
Conditions
Interventions
Xanomeline/ Trospium Chloride
Specified dose on specified days
Locations (3)
Anaheim Clinical Trials
Anaheim, California, United States
ICON - Lenexa
Lenexa, Kansas, United States
ICON Development Solutions
San Antonio, Texas, United States